Humacyte (HUMA) said Tuesday its Symvess bioengineered vessel has been approved for listing in the US Defense Logistics Agency's Electronic Catalog.
The listing gives the US Department of Defense and Veterans Affairs facilities access to Symvess for treating military personnel and other eligible patients, the company said.
Symvess received the US Food and Drug Administration's approval in December 2024 to treat extremity vascular trauma, Humacyte said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.